Table 4.
Clinical studies targeting the JAK/STAT signaling pathway in HCC.
| Drug | Target | NCT Number | Phase | Status | Clinical Outcomes |
|---|---|---|---|---|---|
| Itacitinib | JAK1 | 04358185 | Ib | In progress, | Not yet determined |
| Pravastatin | STAT1 | 01075555 | III | Completed (September 2015) |
MOS 10.7 m vs. 10.5 m (sorafenib vs. pravastatin + sorafenib) |
| Danvatirsen | STAT3 | 01839604 | I | Completed (February 2015) |
Limited antitumor activity. |
| Napabucasin | STAT3 | 02279719 | I/II | Completed (October 2019) |
No significant difference in overall response rates between sorafenib alone and napabucasin + sorafenib groups |
| OPB-31121 | STAT3 | 01406574 | I/II | Completed (March 2014) |
Limited antitumor effects and low overall responses. |
MOS, mean overall survival.